|
Samuel S. Coates has a corporate law practice with an emphasis in the representation of emerging technology and life science companies.
Mr. Coates has experience structuring and negotiating spin-outs, joint ventures and other strategic collaborations as well as mergers and acquisitions. Mr. Coates also has extensive experience with venture capital investments and has represented both companies and investors in numerous equity offerings, both public and private.
Recent representative transactions include:
- Sale of GoldenGate Software to Oracle Corporation (Nasdaq: ORCL)
- Leveraged buyout of the California Medical Association
- Sale of PhonePeople to j2 Global Communications (Nasdaq: JCOM)
- Sale of PropertyBridge to Moneygram International (NYSE: MGI)
- Sale of Berkeley Data Systems to EMC Corporation (NYSE: EMC)
- Spinout of Virobay from Applera CP - Celera Group (NYSE: CRA)
- Sale of Avidia to Amgen (Nasdaq: AMGN)
- PIPE Offering for Genelabs (Nasdaq: GNLB)
- Acquisition of AlgoRX by Anesiva (Nasdaq: ANSV)
- Spinout of Avidia from Maxygen (Nasdaq: MAXY)
- PIPE Offering for Dynavax (Nasdaq: DVAX)
- Sale of Sagres Discovery to Chiron (Nasdaq: CHIR)
Mr. Coates is a partner in the Cooley Business department in the Palo Alto office. Mr. Coates is a frequent speaker on various corporate law and venture capital related subjects.
He received a J.D. from the University of San Francisco School of Law in 1999. He received a B.A. from the University of California, Berkeley.
Mr. Coates is a member of the State Bar of California.
Education- University of San Francisco School of Law
JD, 1999 - University of California, Berkeley
BA
Admissions
Memberships
- American Bar Association
- The Bar Association of San Francisco
|